Apollina Goel

Apollina Goel has a broad range of experience in the biomedical field. Apollina began their career in 1998 as a Postdoctoral Scientist at the University of Nebraska Medical Center, where they characterized divalent and multivalent single-chain antibody fragments of TAG-72 antibody. In 2002, they became an Associate Consultant at the Mayo Clinic and Foundation, where they identified Bortezomib as a potent radiosensitizer in multiple myeloma. In 2007, they joined the University of Iowa as an Assistant Professor (Tenure-Track) and was later promoted to Associate Professor (Tenured) in 2016. In the same year, they became a Visiting Associate Professor at the University of Iowa and a Senior Scientist at Invicro, A Konica Minolta Company. At Invicro, they led discovery research for different platforms, such as biologics, gene- and cell-based therapies, RNA therapeutics, and small molecules. In 2021, they became the Director of Translational Medicine at Cue Biopharma.

Apollina Goel obtained their Doctor of Philosophy (PhD) in Biotechnology from the Institute of Microbial Technology, Chandigarh between 1993 and 1997. Prior to that, they obtained their Master of Science (MSc) in Biotechnology from Savitribai Phule Pune University between 1990 and 1992. Apollina Goel also attended Kendriya Vidyalaya, IIT Kanpur, India, but did not receive a degree there.